13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • CS1003

    Acronym: 

    CS1003

    ACTRN/NCT /ethics: 

    NCT03475251

    Scientific title: 

    This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment

    Summary of trial and patient characteristics

    Cancer Type All cancers
    Trial Type Treatment
    Phase Phase I Tumour Stream Solid Tumours
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type All cancers
    Trial Type Treatment
    Phase Phase I
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Solid Tumours
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A phase Ia/Ib, open-label, multiple-dose escalation and expansion study of the Anti-PD-1 monoclonal antibody CS1003 in subjects with advanced solid tumors.

    Lay Summary

    This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment

    Sponsor / Cooperative group

    Cstone

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Royal Adelaide Hospital Anne Milton anne.milton@sa.gov.au 08 7074 2342 Brown Recruiting